# AtriCure (ATRC)

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atricure-atrc

- Industry: Medical Devices & Equipment
- Headquarters: West Chester, US
- Website: www.atricure.com
- Total disclosed funding: $26M
- Latest round: Series B (Jun 26, 2002)
- Investors on record: 6

## About

AtriCure is a medical device company focused on developing innovative solutions for treating atrial fibrillation and managing pain, primarily through its advanced surgical devices.Founded in 2000 and headquartered in West Chester, US, AtriCure specializes in medical devices aimed at treating atrial fibrillation. The company's CEO is Michael Carrel. Recently, AtriCure completed a PIPE funding round of USD 16.50 mn, raising a total of USD 16.50 mn to date. AtriCure has engaged in 5 different deals since its inception.AtriCure specializes in advanced medical devices aimed at treating atrial fibrillation (AF) and managing pain, primarily through its flagship product, the AtriClip device. This innovative device is designed to occlude the left atrial appendage, thereby reducing the risk of stroke in patients suffering from AF. The company also provides a comprehensive range of surgical ablation tools that facilitate the treatment of atrial fibrillation through minimally invasive procedures. These products serve a diverse customer base, including hospitals, cardiac care clinics, and specialized healthcare providers. AtriCure markets its products across various geographical regions, including North America, Europe, and select areas in Asia, ensuring that their advanced solutions are accessible to a wide array of patients experiencing AF-related complications.AtriCure generated revenue of USD 465.31 mn in the most recent year, 2024, with an EBITDA of USD -20.70 mn for the same period. The company primarily earns revenue through direct sales of its medical devices to healthcare facilities and professionals, utilizing a business-to-business model to establish ongoing relationships with hospitals and outpatient centers.AtriCure plans to expand its product line with new devices targeting the treatment of atrial fibrillation, although specific release dates are not disclosed. The company is also focused on entering new markets, particularly in growing regions of Asia and Europe, to enhance its global footprint. The recent PIPE funding will support these expansion initiatives as all VC firms have exited their stake in the company since its IPO.

## Funding rounds

- Series B, Jun 26, 2002, $21M — US Venture Partners, New England Partners, Charter Life Sciences, Foundation Medical Partners, Camden Partners, Partisan Management Group
- Series A, Jun 5, 2001, $5M — US Venture Partners, Charter Life Sciences, Partisan Management Group

## Investors

- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series A, Series B
- Charter Life Sciences (https://capitalatlas.ai/funds/charter-life-sciences) — Series A, Series B
- Partisan Management Group (https://capitalatlas.ai/funds/partisan-management-group) — Series A, Series B
- New England Partners (https://capitalatlas.ai/funds/new-england-partners) — Series B
- Foundation Medical Partners (https://capitalatlas.ai/funds/foundation-medical-partners) — Series B
- Camden Partners (https://capitalatlas.ai/funds/camden-partners) — Series B